Comparative Pharmacology
Head-to-head clinical analysis: ANAPROX DS versus JUNIOR STRENGTH IBUPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANAPROX DS versus JUNIOR STRENGTH IBUPROFEN.
ANAPROX DS vs JUNIOR STRENGTH IBUPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis involved in pain, inflammation, and fever.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
Oral: 200-400 mg every 4-6 hours as needed; maximum single dose 400 mg, maximum daily dose 1200 mg for OTC use.
None Documented
None Documented
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Terminal elimination half-life is 2-4 hours in children; prolonged in neonates or hepatic impairment.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Renal excretion of conjugated metabolites (approximately 70-90%) and unchanged drug (<10%). Biliary/fecal excretion accounts for <10%.
Category C
Category D/X
NSAID
NSAID